DE602005018043D1 - Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung - Google Patents

Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung

Info

Publication number
DE602005018043D1
DE602005018043D1 DE602005018043T DE602005018043T DE602005018043D1 DE 602005018043 D1 DE602005018043 D1 DE 602005018043D1 DE 602005018043 T DE602005018043 T DE 602005018043T DE 602005018043 T DE602005018043 T DE 602005018043T DE 602005018043 D1 DE602005018043 D1 DE 602005018043D1
Authority
DE
Germany
Prior art keywords
dihydrosphenomylinin
liposomal formulations
therapeutic agent
compositions
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005018043T
Other languages
English (en)
Inventor
Pieter R Cullis
Thomas D Madden
Michael J Hope
Steven M Ansell
Barbara L S Mui
Sean C Semple
Norbert Maurer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arbutus Biopharma Corp
Original Assignee
Tekmira Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tekmira Pharmaceuticals Corp filed Critical Tekmira Pharmaceuticals Corp
Publication of DE602005018043D1 publication Critical patent/DE602005018043D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
DE602005018043T 2004-05-17 2005-05-16 Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung Active DE602005018043D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57171204P 2004-05-17 2004-05-17
US63199704P 2004-11-30 2004-11-30
PCT/US2005/017054 WO2005120461A2 (en) 2004-05-17 2005-05-16 Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof

Publications (1)

Publication Number Publication Date
DE602005018043D1 true DE602005018043D1 (de) 2010-01-14

Family

ID=35169836

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005018043T Active DE602005018043D1 (de) 2004-05-17 2005-05-16 Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung

Country Status (7)

Country Link
US (1) US7811602B2 (de)
EP (1) EP1750673B1 (de)
AT (1) ATE450251T1 (de)
AU (1) AU2005251691A1 (de)
CA (1) CA2566559C (de)
DE (1) DE602005018043D1 (de)
WO (1) WO2005120461A2 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
BRPI0516265A (pt) 2004-10-06 2008-08-26 Bc Cancer Agency composição, uso da mesma, método de aumentar a retenção de um agente terapêutico dentro dos lipossomas, formulação lipossomal, e, uso de um agente terapêutico encapsulado lipossomalmente
WO2006052767A2 (en) * 2004-11-05 2006-05-18 Inex Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
JP5815915B2 (ja) * 2005-10-11 2015-11-17 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 過活動膀胱障害の治療のためのスフィンゴミエリンリポソーム
EP1959961A2 (de) * 2005-12-06 2008-08-27 Rigel Pharmaceuticals, Inc. Formulierung aus unlöslichen kleinmoleküligen wirkstoffen in trägern auf fettbasis
SI2019683T2 (sl) 2006-04-25 2022-10-28 The Regents Of The University Of California Dajanje rastnih faktorjev za zdravljenje motenj CŽS
EP2023949A4 (de) * 2006-04-26 2009-08-26 Univ California Zusammensetzungen und verfahren für konvektionsverstärkte freisetzung von neurotherapeutika mit hohem molekulargewicht
ES2444501T3 (es) * 2006-08-04 2014-02-25 Megmilk Snow Brand Co., Ltd Uso de esfingomielina para el tratamiento de la gripe
ES2588705T3 (es) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
US20110070298A1 (en) 2008-06-05 2011-03-24 Immunovaccine Technologies Inc. Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance
CA2741373A1 (en) 2008-10-30 2010-06-03 Peixuan Guo Membrane-integrated viral dna-packaging motor protein connector biosensor for dna sequencing and other uses
MX2011009724A (es) 2009-03-19 2011-10-14 Merck Sharp & Dohme Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen del factor de transcripcion basico de cierre de leucina 1 de homologia de btb y cnc 1, usando el listado de secuencias de acido nucleico corto de interferencia.
WO2010107952A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010107958A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010107957A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120004281A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
KR20110138223A (ko) 2009-03-27 2011-12-26 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
US20120022143A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120058178A1 (en) 2009-03-30 2012-03-08 Eisai R&D Management Co., Ltd. Liposome Composition
EP2415464B1 (de) * 2009-03-30 2017-05-10 Eisai R&D Management Co., Ltd. Verfahren zur herstellung einer liposomenzusammensetzung
WO2011038073A1 (en) 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes comprising docetaxel
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US20110070294A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes
CA2816925C (en) 2009-11-04 2023-01-10 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
EP2394640A1 (de) * 2010-05-21 2011-12-14 MediGene AG Verbesserte liposomale Formulierungen von lipophilen Verbindungen
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2606134B1 (de) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina)
KR20130137160A (ko) 2010-08-24 2013-12-16 머크 샤프 앤드 돔 코포레이션 내부의 비－핵산 스페이서를 함유하는 단일－가닥 ＲＮＡｉ 작용제
WO2012027467A1 (en) 2010-08-26 2012-03-01 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP3327125B1 (de) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
AU2012321022B2 (en) 2011-10-06 2017-03-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
JP2015502337A (ja) 2011-10-25 2015-01-22 ザ ユニバーシティ オブ ブリティッシュ コロンビア 限界サイズ脂質ナノ粒子および関連方法
DK3988537T1 (da) 2011-12-07 2022-05-23 Alnylam Pharmaceuticals Inc Bionedbrydelige lipider til afgivelse af aktive midler
ES2442450B1 (es) * 2012-08-09 2014-12-12 Enoc Solutions, S.L. Liposomas vacíos como adyuvante de diferentes principios activos, administrados independientemente y en su forma galénica convencional
KR102310697B1 (ko) 2012-11-20 2021-10-12 스펙트럼 파마슈티컬즈 인크 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법
WO2014089216A1 (en) * 2012-12-04 2014-06-12 Tekmira Pharmaceuticals Corporation In vitro release assay for liposome encapsulated vincristine
CA2904184C (en) 2013-03-08 2021-09-07 Novartis Ag Lipids and lipid compositions for the delivery of active agents
WO2014172045A1 (en) 2013-03-15 2014-10-23 The University Of British Columbia Lipid nanoparticles for transfection and related methods
CN105051051B (zh) 2013-03-15 2021-07-16 萨瑞斯治疗控股公司 用于合成神经鞘磷脂和二氢神经鞘磷脂的方法
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
PL3083556T3 (pl) 2013-12-19 2020-06-29 Novartis Ag Lipidy i kompozycje lipidowe dla dostarczania środków czynnych
EP3083579B1 (de) 2013-12-19 2022-01-26 Novartis AG Lipide und lipidzusammensetzungen zur verabreichung von wirkstoffen
PT3766916T (pt) 2014-06-25 2022-11-28 Acuitas Therapeutics Inc Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
CN107072946B (zh) 2014-09-05 2022-01-11 诺华股份有限公司 用于递送活性剂的脂质和脂质组合物
US10221127B2 (en) 2015-06-29 2019-03-05 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
IL286515B2 (en) 2015-10-28 2024-02-01 Acuitas Therapeutics Inc Novel lipids and nanoparticle formulations of lipids for delivery of nucleic acids
EP3389720A1 (de) 2015-12-18 2018-10-24 The General Hospital Corporation Polyacetalpolymere, konjugate, partikel und verwendungen davon
ES2924806T3 (es) 2016-09-02 2022-10-11 Dicerna Pharmaceuticals Inc Análogos de 4'-fosfato y oligonucleótidos que comprenden el mismo
EP3603620A4 (de) * 2017-03-31 2020-03-25 FUJIFILM Corporation Liposomzusammensetzung und pharmazeutische zusammensetzung
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
WO2018200943A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2019036008A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
EP3778611B1 (de) * 2018-03-27 2022-10-12 NOF Corporation Lipid aus sphingomyelin und verfahren zu dessen herstellung
TW202015658A (zh) 2018-06-20 2020-05-01 日商富士軟片股份有限公司 包含內含藥物之脂質體組成物及免疫檢查點抑制劑之組合醫藥
CN112789032A (zh) * 2018-10-01 2021-05-11 富士胶片株式会社 包含内含药物的脂质体组合物及铂制剂的组合医药
US11453639B2 (en) 2019-01-11 2022-09-27 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
WO2020205473A1 (en) 2019-03-29 2020-10-08 Decerna Pharmaceuticals, Inc. Compositions and methods for the treatment of kras associated diseases or disorders
AU2020253613A1 (en) * 2019-04-03 2021-11-25 New York University Liposomes encapsulating adenosine
KR20220004675A (ko) 2019-05-03 2022-01-11 다이서나 파마수이티컬, 인크. 단축 센스 가닥을 갖는 이중 가닥 핵산 억제제 분자
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
IL294599A (en) 2020-01-15 2022-09-01 Dicerna Pharmaceuticals Inc Methylene phosphonate nucleic acids and their analogs
WO2022015809A2 (en) * 2020-07-14 2022-01-20 The Research Foundation for the State Universtiy of New York Asymmetric charged vesicles and methods of preparing and use thereof
IL300283A (en) 2020-08-04 2023-04-01 Dicerna Pharmaceuticals Inc Systemic administration of oligonucleotides
CN117440810A (zh) 2021-05-24 2024-01-23 富士胶片株式会社 抗肿瘤剂
EP4349338A1 (de) 2021-05-24 2024-04-10 FUJIFILM Corporation Behandlungsmittel
WO2023069979A1 (en) 2021-10-20 2023-04-27 University Of Rochester Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) * 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US4885172A (en) * 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5171578A (en) * 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4774085A (en) * 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
JP2792702B2 (ja) * 1988-10-05 1998-09-03 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド 乾燥時に改善された安定性を示すリポソームの調製方法
US4957773A (en) * 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
JP2599492B2 (ja) * 1990-08-21 1997-04-09 第一製薬株式会社 リポソーム製剤の製造法
WO1995008986A1 (en) 1993-09-27 1995-04-06 Smithkline Beecham Corporation Camptothecin formulations
CA2153251C (en) * 1993-11-05 1998-09-01 David Samuel Collins Liposome preparation and material encapsulation method
US5534499A (en) * 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
IL122290A0 (en) * 1995-06-07 1998-04-05 Inex Pharmaceuticals Corp Lipid-nucleic acid complex its preparation and use
CA2202103C (en) * 1996-04-11 2007-01-09 Toshiaki Tagawa Method for preparing closed vesicles
US5837282A (en) * 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6320017B1 (en) * 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
US6610835B1 (en) * 1998-02-12 2003-08-26 Emory University Sphingolipid derivatives and their methods of use
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US6380405B1 (en) * 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
IL153676A0 (en) * 2000-06-30 2003-07-06 Inex Pharmaceuticals Corp Liposomal pharmaceutical compositions
AU2001270310A1 (en) * 2000-07-07 2002-01-21 Guilford Pharmaceuticals Inc. Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same

Also Published As

Publication number Publication date
WO2005120461A3 (en) 2006-03-16
EP1750673B1 (de) 2009-12-02
CA2566559A1 (en) 2005-12-22
AU2005251691A1 (en) 2005-12-22
CA2566559C (en) 2014-05-06
US7811602B2 (en) 2010-10-12
EP1750673A2 (de) 2007-02-14
WO2005120461A2 (en) 2005-12-22
US20060008909A1 (en) 2006-01-12
ATE450251T1 (de) 2009-12-15

Similar Documents

Publication Publication Date Title
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
ES2534303T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
SG164368A1 (en) Treatment of cancer
DE602004031462D1 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
ATE537826T1 (de) Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
DE60222573D1 (de) Mikroemulsionbildende herbizidkonzentrate, mikroemulsionen und verfahren
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
NO20063429L (no) Brusende oral opiat doseringsform
MX2007010996A (es) Nuevas composiciones de liposomas.
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
CR10147A (es) "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos"
IL183506A0 (en) Compositions and methods for treating neoplastic diseases
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
EP1781296A4 (de) Chinazolinderivate und ihre verwendung bei der behandlung von thrombocythämie
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
DE602004023183D1 (de) Gegen antikörper gerichtete photodynamische therapie
NO20055390D0 (no) Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer
SE0301650D0 (sv) Novel compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition